Lantern Pharma is leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and developmentSee how we are doing it
Conquering cancer requires bringing unique talents & individuals together for the advancement of patient careMeet our team
The Harmonic™ Clinical Trial is enrolling participants in a Phase 2 multi-center study to evaluate an investigational new drug for never smokers with non-small cell lung cancer (NSCLC)Learn More About Harmonic™
Lantern Pharma is accelerating the speed, power, precision and cost of oncology drug development.
Oncology drug development is time consuming, costly, and high risk, with rates of a successful outcome (FDA drug approval) being very low. This is a perfect problem area for Lantern Pharma’s approach to drug development involving machine learning, AI, and rapid, data-driven hypothesis testing using in vitro and in vivo models.
Success rate of cancer drugs in clinical trial testing
Cancer is the second leading cause of death after heart disease
Current global oncology drug market
Biomarker-based trials are 12 times more likely to succeed
Oncological clinical trials launched since 2007
Lantern Pharma’s pharmaceutical biotechnology solution is through the development of a process that accurately stratifies patient populations into responders and non-responders for a wide variety of oncology therapies to de-risk clinical trials, develop companion diagnostics and increase the potential for successful FDA approval with reduced costs.